Total GLP-1 Payments Rose Sharply Through 2022 Despite Lower Patient Cost-Sharing
A Northwestern University study published July 16 in the Journal of the American Heart Association found that average total payments for GLP-1 users without diabetes increased significantly between 2017 and 2022, even as patient out-of-pocket costs declined. The study documents the growing financial burden on payers during the period when GLP-1 utilization expanded beyond diabetes treatment. The findings reflect cost trends during a period that predates recent Medicare coverage expansion and current utilization management strategies. The research provides baseline data as Medicaid managed care organizations continue to face pressure to cover GLP-1s for weight loss and cardiovascular indications.
Medicaid MCOs face mounting pressure to cover GLP-1s for non-diabetes indications while total payment trends show significant cost increases that exceed patient cost-sharing reductions, requiring aggressive utilization management and prior authorization strategies.
Managed Care · Pharmacy
You might also like